Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amidst the COVID-19 Pandemic: A Cross-Sectional Study

Mariam Hull, MD1,2; Mered Parnes, MD1,2; Joseph Jankovic, MD2

1Section of Pediatric Neurology and Developmental Neuroscience, Texas Children’s Hospital and Baylor College of Medicine; 2Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas

Corresponding Author: Mariam Hull; mariam.hull@bcm.edu

Neurology® Clinical Practice Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Word Count: 1737
Figure: 2
Table: 1
Key Words: Functional movement disorder, psychogenic movement disorder, conversion disorder, COVID-19

Study Funding: No targeted funding reported.
Disclosures: Dr. Parnes has served on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Parnes has received research support from the NIH and Alexion. Drs. Hull and Jankovic had no disclosures to report.

Take-home points:
1. Functional (psychogenic) movement disorder is a relatively common condition encountered within movement disorders centers and have often been associated with psychological stressors.
2. During the COVID-19 pandemic, there has been an observed increase incidence within our centers.
3. The full psychological effects of the COVID-19 pandemic has yet to be fully realized, however, may contribute to our observed increase in incidence.

Abstract:
Background: Functional (psychogenic) movement disorders (FMDs) are conditions in which affected patients develop abnormal movements that are incongruous with known, organic, movement disorders, often associated with psychological stressors.

Methods: In this case series, electronic medical records of all patients who presented to our adult and pediatric tertiary-care movement disorders clinics between March 1 and October 30, 2020 and during the same period in 2019 were reviewed. All patients diagnosed with functional or psychogenic movement disorder were included if they satisfied diagnostic criteria.

Results: Among 550 new patients referred for evaluation at our tertiary care movement disorders centers, 45 (8.2%) received a diagnosis of FMD; 75.6% were female, in comparison to the prior year during which time 665 new patients were evaluated and 5.1% were diagnosed...
with FMD. This represents a 60.1% increase (90.1% in pediatric cohort, 50.9% in adult cohort) in new patients diagnosed with FMD during the COVID-19 pandemic.

Conclusions: Within our patient population, there has been increased incidence of FMDs in the setting of the COVID-19 pandemic, possibly reflecting increased psychological and other stressors during this period.

Introduction:
In December 2019, cases of a novel respiratory virus, later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were reported in Wuhan, China. Soon thereafter, the disease caused by the virus, COVID-19, became a worldwide pandemic. Globally, regulations were put in place to mitigate the spread of the virus and research efforts aimed at management and treatment of the disease were initiated.

Initially, COVID-19 was thought to be a disease primarily involving the respiratory system with nonspecific neurologic symptoms such as headaches, fatigue, and dizziness, but it was soon recognized to be a multisystem disease. A systematic surveillance study revealed that neurologic and psychiatric involvement is common but variable, and manifested by cerebral vasculitis, stroke (ischemic and hemorrhagic), encephalitis, Guillain-Barre syndrome, psychosis, dementia, catatonia, and mania.

At the time of this writing, the full psychological effect of the COVID-19 pandemic is just beginning to be understood. During the initial peak of the pandemic in China, patients previously diagnosed with depression and anxiety disorders reported an increase in symptoms of post-traumatic stress disorder (PTSD), anxiety, depression, and insomnia. In a series of four consecutive patients admitted for new onset of reactive psychosis during the first two weeks of compulsory nationwide quarantine in Spain, all of the episodes were linked to stressors from the COVID-19 pandemic.

Functional (psychogenic) movement disorders (FMDs) are a common presentation within the broader category of functional neurologic symptom disorder, previously called conversion disorder, hysterical neurosis, somatoform disorder, dissociative disorder, and psychogenic disorder. In the DSM-5, this diagnosis falls within the somatic symptom and related disorders. FMD appears to be a manifestation of a dysfunctional manner of coping with underlying psychological stressors, although a particular underlying stressor is not always determined and is not necessary to make the diagnosis.

Although the psychological effect of this pandemic is increasingly being recognized, the full spectrum of manifestations of coping with the psychological stressors has yet to be fully realized. Here we describe the effect of the COVID-19 pandemic within the field of movement disorders to draw attention to a marked increase of new patients presenting to movement disorders clinics with FMDs compared to the preceding year.
Methods:
A total of 550 new patients were evaluated at our movement disorders clinics from March 1 to October 30, 2020 and 665 new patients were evaluated from March 1 to October 30, 2019. All patients who received a diagnosis of FMD as previously defined were included, and clinical documentation was reviewed. Demographics, diagnostic studies, medical history, and clinical examination were evaluated. We excluded patients for whom alternative diagnoses were proposed. Basic statistical methods utilized include calculation of mean and range. Percentage of patients receiving new diagnoses of FMD was calculated in each group and within the total number of patients for 2019 and 2020 and percent change of incidence between each year in provided groups was also calculated using total number of new patients evaluated at our centers. Comparison of proportions was calculated between the groups in 2019 and 2020 using a chi-squared test to calculate p-values.

Standard protocol approvals, registrations, and patient consents:
Research was performed under the regulations placed by the respective institutional ethics committees.

Data Availability:
Anonymized data not published within this article will be made available by request from any qualified investigator.

Results:
Among 550 new patients (132 at the pediatric movement disorders clinic) evaluated at our movement disorders centers, 45 (12 pediatric, 33 adult) received a new diagnosis of FMD from a subspecialty movement disorders center (8.2%) from March 1 to October 30, 2020. This is in contrast to 665 new patients evaluated (168 pediatric, 497 adult) in the prior year, during which only 34 (5.1%) were diagnosed with FMD (8 pediatric and 26 adult). This represents a 60.1% increase (p=0.029, 95% Confidence interval 0.27% to 6.02%) (90.1% in pediatric cohort, 50.9% in adult cohort) in new patients diagnosed with FMD during the COVID-19 pandemic (Figure 1).

Average age at presentation was 34.2 years (13.9 years pediatric and 41.6 years adult). Adult clinic cohort range of age at presentation ranged from 9 to 77 years, and pediatric clinic cohort age at presentation ranged was 9 to 17 years. Females presenting with FMD comprised 75.6% of those diagnosed (N=34). Of the patients newly diagnosed with FMD, 62.2% had at least one prior psychiatric diagnosis (N=28) while 42.2% had a pre-existing medical condition (N=19) (Figure 2). Clear precipitating factors were identified in 48.9% (N=22) of patients.

Unique triggers identified in our cohort included one patient who developed functional tremor while hospitalized for COVID-19. Another patient developed functional tics after watching a teenager on TikTok (a social media platform) displaying and discussing her own diagnosis of “Tourette syndrome.”

The most common phenomenological classification of FMD was tremor, followed by dystonia (Table 1). Mean duration of symptoms was 60.7 months (range: 1 to 468 months).
Discussion:
While the neurological and psychological impacts of COVID-19 are currently being studied and many well described to include cerebral vasculitis, stroke, encephalitis, Guillain-Barre syndrome, and others, the impact of the disease on neurologic movement disorders have been restricted to case reports including myoclonus, tremor, ataxia, and parkinsonism.  

FMD is a common diagnosis in specialty movement disorders referral centers; they can be difficult to distinguish from organic conditions, especially for clinicians with less movement disorders expertise. Thorough history-taking often elicits characteristic features such as an abrupt onset with rapid progression to maximum severity, paroxysmal or episodic symptoms with symptom-free periods between episodes (including associated mutism, stuttering, or other episodic impairments of speech or language production), unusual triggers (psychological or physical trauma, flashing lights, physical touch, proximity to people or objects, loud noises, etc.), or many seemingly unrelated neurologic symptoms which may change over time. Examination also typically demonstrates supportive signs such as distractibility, suggestibility, and variability in frequency, pattern, and/or amplitude, among others. The existence of a pattern of positive symptoms and signs on history and examination, rather than the absence of another etiology, is crucial in making the diagnosis. 

Limitations of this study include potential for recall bias given the method being a cross-sectional study, therefore similar time periods were chosen from the year prior. Furthermore, as our centers are specialized movement disorders centers, patients are often pre-selected for evaluation within these clinics with a chief complaint of abnormal movements, which results in a higher rate of functional movement disorders and as such may not necessarily be generalizable to non-subspecialized centers. Lastly, during the time period in 2020, our clinics (among numerous others) adopted telemedicine as an option for clinical evaluation, which may also have pre-selected patients with access to such technology, and due to the COVID-19 pandemic some patients may have elected postpone any clinical evaluations.

The underlying pathophysiology of FMDs remains unclear, but our understanding of possible mechanisms has been improving as result of growing interest and research advances. The relationship to stress as a potential precipitating factor is supported by our finding of increased incidence of FMD cases during the challenging pandemic. We propose that differences between the pediatric and the adult cohorts may be due to underlying differences in cognitive coping strategies between the two populations.

Organic brain differences have been noted among patients with FMDs compared to unaffected controls, including altered connectivity between the limbic and motor networks. Patients with FMD have been found to have decreased activation of the supplementary motor area in comparison to controls. Furthermore, patients with functional neurologic symptom disorder appear to have increased connectivity between the insula, inferior frontal gyrus, parietal cortex, and precentral sulcus (areas involved with emotion, executive planning, and movement). While the pathophysiology of FMDs is still not fully understood, exposures to trauma (physical and/or psychological) have been proposed to reshape the connectivity until a threshold is reached after which a motor response is manifested.
Prior outbreaks including Zika, Ebola, avian influenza, and H1N1 have been found to cause psychological stress within the population. Early data suggests that COVID-19 has also been the cause of increased psychological morbidity including increased feelings of anxiety and symptoms in patients with a prior diagnosis of FMD. To date, there is one report of a patient who developed FMD while quarantined with the disease. One of the patients included in our adult cohort developed FMD while hospitalized for symptoms of COVID-19.

Effects on the population since the onset of the outbreak include job losses, school closures, and increased feelings of loneliness and isolation; many have endorsed new feelings of increased anxiety, depression and stress. These feelings can persist through the periods of recovery from an outbreak, as has been reported with the resolution of SARS in Taiwan.

The first reports of widespread functional neurologic symptom disorder in a population were in the context of mass psychogenic illness (“mass hysteria”) surrounding the bubonic plague pandemic known as the Black Death, in 1374 AD. More recent reports of mass psychogenic illness have primarily involved close-knit groups of adolescent females. In 2012, a group of girls in a school in Le Roy, New York developed acute onset functional tics, and many of the girls found themselves as popular faces of social media.

The role of social media within functional neurologic symptom disorder and FMD is unclear, however during a pandemic of which there is implementation of social distancing, there does seem to be increased use of the various social media platforms (up to 82% of participants in one study reported frequent social media exposure). In this study, social media exposure was also correlated with higher odds of anxiety and depression. One of the patients within our cohort also presented with the abrupt onset of functional tics after watching a social media personality on TikTok who had been diagnosed with Tourette syndrome; our patient acutely developed similar movements and noises. We suggest that functional tics developing after watching similar movements on social media platforms be referred to as “TikTok tics.” We expect that in the advent of increased utilization of social media during the pandemic, these types of presentations may become more common.

**Conclusions:**
We describe increased incidence of FMDs within our movement disorders centers in the setting of the COVID-19 pandemic, in both the pediatric and adult age groups. While specific stressors are not always evident, and are not necessary to make the diagnosis, the current rise in incidence of FMDs may support the role of psychological stressors related to social isolation, financial strain and other pandemic-related burdens within this disorder.
References:


Table: Total number of patients with functional movement disorder, classified by presenting phenomenology.

<table>
<thead>
<tr>
<th>Classification</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor</td>
<td>24</td>
<td>53.3%</td>
</tr>
<tr>
<td>Dystonia</td>
<td>14</td>
<td>31.1%</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>8</td>
<td>17.8%</td>
</tr>
<tr>
<td>Tics</td>
<td>4</td>
<td>8.9%</td>
</tr>
<tr>
<td>Stereotypy</td>
<td>4</td>
<td>8.9%</td>
</tr>
<tr>
<td>Multiple</td>
<td>9</td>
<td>20.0%</td>
</tr>
</tbody>
</table>

Figure 1. Total number of new patients presenting to movement disorders clinics (March 1 to October 30) in 2019 vs. 2020 diagnosed with FMD (functional movement disorders).
Figure 2. Pre-existing psychiatric diagnoses of patients presenting with FMD to movement disorders clinics (March 1 to October 30, 2020)
Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amidst the COVID-19 Pandemic: A Cross-Sectional Study
Mariam Hull, Mered Parnes and Joseph Jankovic

This information is current as of April 14, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://cp.neurology.org/content/early/2021/04/13/CPJ.0000000000001082.full.html

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Movement Disorders
http://cp.neurology.org/cgi/collection/all_movement_disorders
Conversion
http://cp.neurology.org/cgi/collection/conversion
Pediatric conversion
http://cp.neurology.org/cgi/collection/pediatric_conversion

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://cp.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://cp.neurology.org/misc/addir.xhtml#reprintsus